Processing your request


please wait...

Case Page

 

Case Status:    DISMISSED    
On or around 10/16/2018 (Notice of voluntarily dismissal)

Filing Date: March 27, 2018

According to the Complaint, Solid Biosciences, Inc. purportedly seeks to cure Duchenne muscular dystrophy, or DMD. The Company’s lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients’ muscles. The Company’s therapy uses adeno-associated virus (AAV) to deliver the transgene into the patient.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that Solid Biosciences’ lead drug candidate SGT-001 had a high likelihood of causing adverse events in patients; (2) that Solid Biosciences misled investors regarding the toxicity of SGT-001; and (3) that, as a result of the foregoing, Defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading.

This case was voluntarily dismissed on October 16, 2018.

Protected Content


Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.